AnGes plans to conduct due diligence on the pandemic influenza DNA vaccines, and both parties intend to negotiate terms and conditions potentially leading to a license, subject to completion of a mutually satisfactory definitive agreement.
AnGes’s experience in working with Vical’s DNA delivery technology within the Japanese regulatory environment positions the company well to pursue further development in Japan based on Vical’s recently announced preliminary Phase I H5N1 pandemic influenza data.